Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Plasmodium vivax.

Flannery EL, Markus MB, Vaughan AM.

Trends Parasitol. 2019 Jul;35(7):583-584. doi: 10.1016/j.pt.2019.04.005. Epub 2019 Jun 5. No abstract available.

PMID:
31176582
2.

The Plasmodium liver-specific protein 2 (LISP2) is an early marker of liver stage development.

Gupta DK, Dembele L, Voorberg-van der Wel A, Roma G, Yip A, Chuenchob V, Kangwanrangsan N, Ishino T, Vaughan AM, Kappe SH, Flannery EL, Sattabongkot J, Mikolajczak S, Bifani P, Kocken CH, Diagana TT.

Elife. 2019 May 16;8. pii: e43362. doi: 10.7554/eLife.43362.

3.

Transcriptomic analysis reveals reduced transcriptional activity in the malaria parasite Plasmodium cynomolgi during progression into dormancy.

Bertschi NL, Voorberg-van der Wel A, Zeeman AM, Schuierer S, Nigsch F, Carbone W, Knehr J, Gupta DK, Hofman SO, van der Werff N, Nieuwenhuis I, Klooster E, Faber BW, Flannery EL, Mikolajczak SA, Chuenchob V, Shrestha B, Beibel M, Bouwmeester T, Kangwanrangsan N, Sattabongkot J, Diagana TT, Kocken CH, Roma G.

Elife. 2018 Dec 27;7. pii: e41081. doi: 10.7554/eLife.41081.

4.

A recombinant antibody against Plasmodium vivax UIS4 for distinguishing replicating from dormant liver stages.

Schafer C, Dambrauskas N, Steel RW, Carbonetti S, Chuenchob V, Flannery EL, Vigdorovich V, Oliver BG, Roobsoong W, Maher SP, Kyle D, Sattabongkot J, Kappe SHI, Mikolajczak SA, Sather DN.

Malar J. 2018 Oct 17;17(1):370. doi: 10.1186/s12936-018-2519-7.

5.

Characterization of Plasmodium vivax Proteins in Plasma-Derived Exosomes From Malaria-Infected Liver-Chimeric Humanized Mice.

Gualdrón-López M, Flannery EL, Kangwanrangsan N, Chuenchob V, Fernandez-Orth D, Segui-Barber J, Royo F, Falcón-Pérez JM, Fernandez-Becerra C, Lacerda MVG, Kappe SHI, Sattabongkot J, Gonzalez JR, Mikolajczak SA, Del Portillo HA.

Front Microbiol. 2018 Jun 25;9:1271. doi: 10.3389/fmicb.2018.01271. eCollection 2018.

6.

PfCap380 as a marker for Plasmodium falciparum oocyst development in vivo and in vitro.

Itsara LS, Zhou Y, Do J, Dungel S, Fishbaugher ME, Betz WW, Nguyen T, Navarro MJ, Flannery EL, Vaughan AM, Kappe SHI, Ghosh AK.

Malar J. 2018 Apr 2;17(1):135. doi: 10.1186/s12936-018-2277-6.

7.

Plasmodium falciparum Liver Stage Infection and Transition to Stable Blood Stage Infection in Liver-Humanized and Blood-Humanized FRGN KO Mice Enables Testing of Blood Stage Inhibitory Antibodies (Reticulocyte-Binding Protein Homolog 5) In Vivo.

Foquet L, Schafer C, Minkah NK, Alanine DGW, Flannery EL, Steel RWJ, Sack BK, Camargo N, Fishbaugher M, Betz W, Nguyen T, Billman ZP, Wilson EM, Bial J, Murphy SC, Draper SJ, Mikolajczak SA, Kappe SHI.

Front Immunol. 2018 Mar 14;9:524. doi: 10.3389/fimmu.2018.00524. eCollection 2018.

8.

Immunization of Malaria-Preexposed Volunteers With PfSPZ Vaccine Elicits Long-Lived IgM Invasion-Inhibitory and Complement-Fixing Antibodies.

Zenklusen I, Jongo S, Abdulla S, Ramadhani K, Lee Sim BK, Cardamone H, Flannery EL, Nguyen T, Fishbaugher M, Steel RWJ, Betz W, Carmago N, Mikolajczak S, Kappe SHI, Hoffman SL, Sack BK, Daubenberger C.

J Infect Dis. 2018 Apr 23;217(10):1569-1578. doi: 10.1093/infdis/jiy080.

9.

Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics.

Cowell AN, Istvan ES, Lukens AK, Gomez-Lorenzo MG, Vanaerschot M, Sakata-Kato T, Flannery EL, Magistrado P, Owen E, Abraham M, LaMonte G, Painter HJ, Williams RM, Franco V, Linares M, Arriaga I, Bopp S, Corey VC, Gnädig NF, Coburn-Flynn O, Reimer C, Gupta P, Murithi JM, Moura PA, Fuchs O, Sasaki E, Kim SW, Teng CH, Wang LT, Akidil A, Adjalley S, Willis PA, Siegel D, Tanaseichuk O, Zhong Y, Zhou Y, Llinás M, Ottilie S, Gamo FJ, Lee MCS, Goldberg DE, Fidock DA, Wirth DF, Winzeler EA.

Science. 2018 Jan 12;359(6372):191-199. doi: 10.1126/science.aan4472.

10.

Assessing drug efficacy against Plasmodium falciparum liver stages in vivo.

Flannery EL, Foquet L, Chuenchob V, Fishbaugher M, Billman Z, Navarro MJ, Betz W, Olsen TM, Lee J, Camargo N, Nguyen T, Schafer C, Sack BK, Wilson EM, Saunders J, Bial J, Campo B, Charman SA, Murphy SC, Phillips MA, Kappe SH, Mikolajczak SA.

JCI Insight. 2018 Jan 11;3(1). pii: 92587. doi: 10.1172/jci.insight.92587. eCollection 2018 Jan 11.

11.

Humoral protection against mosquito bite-transmitted Plasmodium falciparum infection in humanized mice.

Sack BK, Mikolajczak SA, Fishbaugher M, Vaughan AM, Flannery EL, Nguyen T, Betz W, Jane Navarro M, Foquet L, Steel RWJ, Billman ZP, Murphy SC, Hoffman SL, Chakravarty S, Sim BKL, Behet M, Reuling IJ, Walk J, Scholzen A, Sauerwein RW, Ishizuka AS, Flynn B, Seder RA, Kappe SHI.

NPJ Vaccines. 2017 Oct 9;2:27. doi: 10.1038/s41541-017-0028-2. eCollection 2017.

12.

A Global Survey of ATPase Activity in Plasmodium falciparum Asexual Blood Stages and Gametocytes.

Ortega C, Frando A, Webb-Robertson BJ, Anderson LN, Fleck N, Flannery EL, Fishbaugher M, Murphree TA, Hansen JR, Smith RD, Kappe SHI, Wright AT, Grundner C.

Mol Cell Proteomics. 2018 Jan;17(1):111-120. doi: 10.1074/mcp.RA117.000088. Epub 2017 Oct 27.

13.

Proteogenomic analysis of the total and surface-exposed proteomes of Plasmodium vivax salivary gland sporozoites.

Swearingen KE, Lindner SE, Flannery EL, Vaughan AM, Morrison RD, Patrapuvich R, Koepfli C, Muller I, Jex A, Moritz RL, Kappe SHI, Sattabongkot J, Mikolajczak SA.

PLoS Negl Trop Dis. 2017 Jul 31;11(7):e0005791. doi: 10.1371/journal.pntd.0005791. eCollection 2017 Jul.

14.

Antimalarial drug discovery - approaches and progress towards new medicines.

Flannery EL, Chatterjee AK, Winzeler EA.

Nat Rev Microbiol. 2017 Sep;15(9):572. doi: 10.1038/nrmicro.2017.88. Epub 2017 Jul 24. No abstract available.

PMID:
28736448
15.

An Opsonic Phagocytosis Assay for Plasmodium falciparum Sporozoites.

Steel RW, Sack BK, Tsuji M, Navarro MJ, Betz W, Fishbaugher ME, Flannery EL, Kappe SH.

Clin Vaccine Immunol. 2017 Feb 6;24(2). pii: e00445-16. doi: 10.1128/CVI.00445-16. Print 2017 Feb.

16.

High-Throughput Assay and Discovery of Small Molecules that Interrupt Malaria Transmission.

Plouffe DM, Wree M, Du AY, Meister S, Li F, Patra K, Lubar A, Okitsu SL, Flannery EL, Kato N, Tanaseichuk O, Comer E, Zhou B, Kuhen K, Zhou Y, Leroy D, Schreiber SL, Scherer CA, Vinetz J, Winzeler EA.

Cell Host Microbe. 2016 Jan 13;19(1):114-26. doi: 10.1016/j.chom.2015.12.001. Epub 2015 Dec 31.

17.

Next-Generation Sequencing of Plasmodium vivax Patient Samples Shows Evidence of Direct Evolution in Drug-Resistance Genes.

Flannery EL, Wang T, Akbari A, Corey VC, Gunawan F, Bright AT, Abraham M, Sanchez JF, Santolalla ML, Baldeviano GC, Edgel KA, Rosales LA, Lescano AG, Bafna V, Vinetz JM, Winzeler EA.

ACS Infect Dis. 2015 Aug 14;1(8):367-79. doi: 10.1021/acsinfecdis.5b00049. Epub 2015 Aug 3.

18.

Mutations in the P-type cation-transporter ATPase 4, PfATP4, mediate resistance to both aminopyrazole and spiroindolone antimalarials.

Flannery EL, McNamara CW, Kim SW, Kato TS, Li F, Teng CH, Gagaring K, Manary MJ, Barboa R, Meister S, Kuhen K, Vinetz JM, Chatterjee AK, Winzeler EA.

ACS Chem Biol. 2015 Feb 20;10(2):413-20. doi: 10.1021/cb500616x. Epub 2014 Nov 5.

19.

KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission.

Kuhen KL, Chatterjee AK, Rottmann M, Gagaring K, Borboa R, Buenviaje J, Chen Z, Francek C, Wu T, Nagle A, Barnes SW, Plouffe D, Lee MC, Fidock DA, Graumans W, van de Vegte-Bolmer M, van Gemert GJ, Wirjanata G, Sebayang B, Marfurt J, Russell B, Suwanarusk R, Price RN, Nosten F, Tungtaeng A, Gettayacamin M, Sattabongkot J, Taylor J, Walker JR, Tully D, Patra KP, Flannery EL, Vinetz JM, Renia L, Sauerwein RW, Winzeler EA, Glynne RJ, Diagana TT.

Antimicrob Agents Chemother. 2014 Sep;58(9):5060-7. doi: 10.1128/AAC.02727-13. Epub 2014 Jun 9.

20.

Identification of pathogen genomic variants through an integrated pipeline.

Manary MJ, Singhakul SS, Flannery EL, Bopp SE, Corey VC, Bright AT, McNamara CW, Walker JR, Winzeler EA.

BMC Bioinformatics. 2014 Mar 3;15:63. doi: 10.1186/1471-2105-15-63.

21.

Antimalarial drug discovery - approaches and progress towards new medicines.

Flannery EL, Chatterjee AK, Winzeler EA.

Nat Rev Microbiol. 2013 Dec;11(12):849-62. doi: 10.1038/nrmicro3138. Epub 2013 Nov 11. Review. Erratum in: Nat Rev Microbiol. 2014 Jan;12(1):70. Nat Rev Microbiol. 2017 Sep;15(9):572.

22.

Using genetic methods to define the targets of compounds with antimalarial activity.

Flannery EL, Fidock DA, Winzeler EA.

J Med Chem. 2013 Oct 24;56(20):7761-71. doi: 10.1021/jm400325j. Epub 2013 Sep 6. Review.

23.

Infection rate and colonization with antibiotic-resistant organisms in skilled nursing facility residents with indwelling devices.

Wang L, Lansing B, Symons K, Flannery EL, Fisch J, Cherian K, McNamara SE, Mody L.

Eur J Clin Microbiol Infect Dis. 2012 Aug;31(8):1797-804. doi: 10.1007/s10096-011-1504-7. Epub 2012 Jan 25.

24.
25.
26.

Patterns of ciprofloxacin-resistant gram-negative bacteria colonization in nursing home residents.

Dommeti P, Wang L, Flannery EL, Symons K, Mody L.

Infect Control Hosp Epidemiol. 2011 Feb;32(2):177-80. doi: 10.1086/657946.

27.
28.

Helicobacter pylori HP1512 is a nickel-responsive NikR-regulated outer membrane protein.

Davis GS, Flannery EL, Mobley HL.

Infect Immun. 2006 Dec;74(12):6811-20. Epub 2006 Oct 9.

29.

Occupational therapy for chronic obstructive lung disease.

Pomerantz P, Flannery EL, Findling PK.

Am J Occup Ther. 1975 Aug;29(7):407-11.

PMID:
1155574

Supplemental Content

Loading ...
Support Center